Miklos Z Molnar1, Elvira O Gosmanova2, Keiichi Sumida1, Praveen K Potukuchi1, Jun Ling Lu1, Jennie Jing3, Vanessa A Ravel3, Melissa Soohoo3, Connie M Rhee3, Elani Streja3, Kamyar Kalantar-Zadeh3, Csaba P Kovesdy4. 1. Division of Nephrology, University of Tennessee Health Science Center, Memphis, TN. 2. Nephrology Section, Stratton VA Medical Center, Albany, NY; Nephrology Division, Department of Medicine, Albany Medical College, Albany, NY. 3. Harold Simmons Center for Chronic Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California-Irvine, Orange, CA. 4. Division of Nephrology, University of Tennessee Health Science Center, Memphis, TN; Nephrology Section, Memphis VA Medical Center, Memphis, TN. Electronic address: ckovesdy@uthsc.edu.
Abstract
BACKGROUND: Medication nonadherence is a known risk factor for adverse outcomes in the general population. However, little is known about the association of predialysis medication adherence among patients with advanced chronic kidney disease and mortality following their transition to dialysis. STUDY DESIGN: Observational study. SETTING & PARTICIPANTS: 32,348 US veterans who transitioned to dialysis during 2007 to 2011. PREDICTORS: Adherence to treatment with cardiovascular drugs, ascertained from pharmacy database records using proportion of days covered (PDC) and persistence during the predialysis year. OUTCOMES: Post-dialysis therapy initiation all-cause and cardiovascular mortality, using Cox models with adjustment for confounders. RESULTS: Mean age of the cohort was 72±11 (SD) years; 96% were men, 74% were white, 23% were African American, and 69% had diabetes. During a median follow-up of 23 (IQR, 9-36) months, 18,608 patients died. Among patients with PDC>80%, there were 14,006 deaths (mortality rate, 283 [95% CI, 278-288]/1,000 patient-years]); among patients with PDC>60% to 80%, there were 3,882 deaths (mortality rate, 294 [95% CI, 285-304]/1,000 patient-years); among patients with PDC≤60%, there were 720 deaths (mortality rate, 291 [95% CI, 271-313]/1,000 patient-years). Compared with patients with PDC>80%, the adjusted HR for post-dialysis therapy initiation all-cause mortality for patients with PDC>60% to 80% was 1.12 (95% CI, 1.08-1.16), and for patients with PDC≤60% was 1.21 (95% CI, 1.11-1.30). In addition, compared with patients showing medication persistence, adjusted HR risk for post-dialysis therapy initiation all-cause mortality for patients with nonpersistence was 1.11 (95% CI, 1.05-1.16). A similar trend was detected for cardiovascular mortality and in subgroup analyses. LIMITATIONS: Large number of missing values; results may not be generalizable to women or the general US population. CONCLUSIONS: Predialysis cardiovascular medication nonadherence is an independent risk factor for postdialysis mortality in patients with advanced chronic kidney disease transitioning to dialysis therapy. Further studies are needed to assess whether interventions targeting adherence improve survival after dialysis therapy initiation. Published by Elsevier Inc.
BACKGROUND: Medication nonadherence is a known risk factor for adverse outcomes in the general population. However, little is known about the association of predialysis medication adherence among patients with advanced chronic kidney disease and mortality following their transition to dialysis. STUDY DESIGN: Observational study. SETTING & PARTICIPANTS: 32,348 US veterans who transitioned to dialysis during 2007 to 2011. PREDICTORS: Adherence to treatment with cardiovascular drugs, ascertained from pharmacy database records using proportion of days covered (PDC) and persistence during the predialysis year. OUTCOMES: Post-dialysis therapy initiation all-cause and cardiovascular mortality, using Cox models with adjustment for confounders. RESULTS: Mean age of the cohort was 72±11 (SD) years; 96% were men, 74% were white, 23% were African American, and 69% had diabetes. During a median follow-up of 23 (IQR, 9-36) months, 18,608 patients died. Among patients with PDC>80%, there were 14,006 deaths (mortality rate, 283 [95% CI, 278-288]/1,000 patient-years]); among patients with PDC>60% to 80%, there were 3,882 deaths (mortality rate, 294 [95% CI, 285-304]/1,000 patient-years); among patients with PDC≤60%, there were 720 deaths (mortality rate, 291 [95% CI, 271-313]/1,000 patient-years). Compared with patients with PDC>80%, the adjusted HR for post-dialysis therapy initiation all-cause mortality for patients with PDC>60% to 80% was 1.12 (95% CI, 1.08-1.16), and for patients with PDC≤60% was 1.21 (95% CI, 1.11-1.30). In addition, compared with patients showing medication persistence, adjusted HR risk for post-dialysis therapy initiation all-cause mortality for patients with nonpersistence was 1.11 (95% CI, 1.05-1.16). A similar trend was detected for cardiovascular mortality and in subgroup analyses. LIMITATIONS: Large number of missing values; results may not be generalizable to women or the general US population. CONCLUSIONS: Predialysis cardiovascular medication nonadherence is an independent risk factor for postdialysis mortality in patients with advanced chronic kidney disease transitioning to dialysis therapy. Further studies are needed to assess whether interventions targeting adherence improve survival after dialysis therapy initiation. Published by Elsevier Inc.
Entities:
Keywords:
Transition to dialysis; advanced chronic kidney disease; anti-hypertensive medications; aspirin; cardiovascular mortality; cardiovascular pharmacotherapy; drug therapy; medication adherence; medication possession ratio (MPR); mortality; pharmacy database analysis; proportion of days covered (PDC); statins; treatment compliance
Authors: P Jungers; Z A Massy; T Nguyen-Khoa; G Choukroun; C Robino; F Fakhouri; M Touam; A T Nguyen; J P Grünfeld Journal: Nephrol Dial Transplant Date: 2001-12 Impact factor: 5.992
Authors: B J Barrett; P S Parfrey; J Morgan; P Barré; A Fine; M B Goldstein; S P Handa; K K Jindal; C M Kjellstrand; A Levin; H Mandin; N Muirhead; R M Richardson Journal: Am J Kidney Dis Date: 1997-02 Impact factor: 8.860
Authors: Mae Thamer; James S Kaufman; Yi Zhang; Qian Zhang; Dennis J Cotter; Heejung Bang Journal: Am J Kidney Dis Date: 2015-06-26 Impact factor: 8.860
Authors: Louise Roy; Brian White-Guay; Marc Dorais; Alice Dragomir; Myriam Lessard; Sylvie Perreault Journal: Kidney Int Date: 2013-05-22 Impact factor: 10.612
Authors: Brian D Bradbury; Rachel B Fissell; Justin M Albert; Mary S Anthony; Cathy W Critchlow; Ronald L Pisoni; Friedrich K Port; Brenda W Gillespie Journal: Clin J Am Soc Nephrol Date: 2006-11-29 Impact factor: 8.237
Authors: Miklos Z Molnar; James D Eason; Abduzhappar Gaipov; Manish Talwar; Praveen K Potukuchi; Kiran Joglekar; Adam Remport; Zoltan Mathe; Istvan Mucsi; Marta Novak; Kamyar Kalantar-Zadeh; Csaba P Kovesdy Journal: Transpl Int Date: 2018-02-27 Impact factor: 3.782
Authors: Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Elani Streja; Connie M Rhee; Melissa Soohoo; Joline L T Chen; Miklos Z Molnar; Yoshitsugu Obi; Daniel Gillen; Danh V Nguyen; Keith C Norris; John J Sim; Steve S Jacobsen Journal: Nephrol Dial Transplant Date: 2017-04-01 Impact factor: 5.992
Authors: Connie M Rhee; Csaba P Kovesdy; Vanessa A Ravel; Elani Streja; Steven M Brunelli; Melissa Soohoo; Keiichi Sumida; Miklos Z Molnar; Gregory A Brent; Danh V Nguyen; Kamyar Kalantar-Zadeh Journal: Diabetes Care Date: 2017-06-07 Impact factor: 19.112
Authors: Elani Streja; Csaba Pal Kovesdy; Melissa Soohoo; Yoshitsugu Obi; Connie M Rhee; Christina Park; Joline L T Chen; Tracy Nakata; Danh V Nguyen; Alpesh N Amin; Steven J Jacobsen; John J Sim; Kamyar Kalantar-Zadeh Journal: Clin J Am Soc Nephrol Date: 2018-06-14 Impact factor: 8.237